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GUEST EDITORIAL
Prognostic factors in breast cancer
W.R.Miller
ICRF Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK.
The present edition of the British Journal of Cancer contains
an article by Stanton et al. on the prognostic significance of
DNA ploidy and S-phase analysis in breast cancer. Insofar as
hardly a week goes by without a similar manuscript appear-
ing for review, the decision to publish this paper could be
questioned, especially as it reports largely negative findings.
In this Editorial I would like to discuss the Stanton et al.
paper whilst at the same time taking the opportunity to
emphasise the need for prognostic factors in breast cancer
and to highlight the problems associated with the assessment
of indices such as S-phase fraction.
The demand for prognostic factors emanates from the
great heterogeneity in the natural history of breast cancer
and the wide variety of therapeutic approaches used to treat
the malignancy. Most breast cancer patients present with
evidently local disease. Despite this, the outlook for individ-
ual patients varies enormously. Although presenting without
evidence of distant disseminated cancer, a proportion of
women will die relatively rapidly of metastatic disease; these
women presumably had occult lesions at the time of presen-
tation. Conversely many women will survive for 20-25 years
even without adjuvant therapy. The spectrum of primary
treatment on offer to patients presenting with breast cancer is
equally varied, ranging from local removal of tumour to high
dose chemotherapy with bone marrow rescue. There is a need
to match individual patients with appropriate treatments to
avoid the equally unacceptable scenaria of either under-
treating patients who have inherently aggressive disease or
exposing others with indolent tumours to the unnecessary
toxic side-effects of potentially ineffective treatment.
Despite the need for predictors of prognosis, the only
widely utilised factors are related to clinical staging. In par-
ticular, the histological presence or absence of metastatic
deposits of tumour in axillary lymph nodes markedly affects
outcome. The poorer prognosis of patients with invaded
lymph nodes has led to official recommendation that most of
these patients should receive some form of adjuvant treat-
ment as part of their primary management (Clinical Alert
from the National Cancer Institute, May 16th 1988). Con-
versely, since approximately 70% of patients without lymph
node involvement survive long-term, it has been argued that
this group could be spared aggressive therapy.
However, there are substantial minorities whose disease
behaves exceptionally, and it has been suggested that lymph
node status largely monitors the extent of disease. Hence the
need for additional factors which reflect more accurately the
inherent biological aggressiveness of tumours. This require-
ment has resulted in a plethora of indices, most of which
(unlike nuclear ploidy and S-phase) have quickly disappeared
after initial citation. This situation provoked an excellent
article by the late Bill McGuire (McGuire, 1991) who put
forward a series of guide-lines by which to judge putative
prognostic factors. These included the need for factors to
have a biological relevance, to have been validated prospec-
tively in large unselected groups of patients, to be confirmed
independently by other workers and to be associated with
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reproducible methodology. It is worthwhile applying these
guidelines to the present literature on nuclear ploidy and
S-phase analysis and in particular the paper in the present
volume.
The biological rationale behind the measurement of
nuclear ploidy is that deviation from the normal nuclear
complement of DNA is likley to reflect cellular abberation
and resistance to growth controls. In general this seems to be
true and most, but not all, studies on nuclear ploidy suggest
that aneuploidy is associated with poor prognosis. Equally,
however, ploidy seems to be highly related to parameters
such as tumour size and other aspects of histological grading
and it tends to lose its predictive powers in multivariate
analysis (O'Reilly & Richards, 1992). Because of this, nuclear
ploidy will not be considered further.
The grounds for expecting that features of cellular pro-
liferation will be useful as prognostic markers is the hope
that they will reflect rate of tumour growth. It is argued that
the faster the tumour grows the quicker it will spread and the
quicker it will kill. Whilst this may be true, it is necessary to
emphasise that tumour growth depends not only upon cel-
lular proliferation but cell loss from the tumour. Secondly
there may be confounding factors, for example rapidly pro-
liferating cells may be more susceptible than slowly dividing
cells to chemotherapeutic regimes and this may improve
prognosis providing the appropriate chemotherapy is imple-
mented early. Measurements of proliferation are invariably
made on the primary tumour whereas patient prognosis is
likely to be dependent upon the behaviour of metastatic
lesions. A scenario could be envisaged whereby a rapidly
proliferating primary tumour of low metastatic potential will
offer a better survival than a slow growing, but highly metas-
tatic, cancer. Lastly, in terms of S-phase, rate of proliferation
will depend not only upon the number of cells in S-phase but
the time in S-phase and this may explain why occasional
studies have been unable to show a good correlation between
S-phase and other markers of proliferation.
Although these considerations suggest that markers of pro-
liferation alone will not correlate absolutely with clinical
outcome, most researchers would agree that indices of
tumour cell proliferation should be leading candidates in the
search for prognostic factors. Hence the profusion of reports
in the literature, (see reviews by Merkel and McGuire, 1990:
Frierson, 1991 & O'Reilly & Richards, 1992). These indicate
that whilst there are exceptions the consensus would be that
high tumour proliferation is associated with poor prognosis;
indeed in lymph node-negative patients markers of prolifera-
tion may represent the most powerful prognostic factors so
far identified (O'Reilly et al., 1990; Clark et al., 1992). So
why publish the largely negative results of Stanton et al.?
This is an issue that the authors themselves have considered
when discussing their results. They point out that many
previous studies have been based on small numbers of
patients and inadequate follow-up. The latter point is well
taken-it is important in a disease with substantial long-
term survival to monitor clinical outcome over an adequate
period. However, it should be emphasised that studies includ-
ing small numbers can be valid. If the prognostic power of
the marker is sufficiently strong, large numbers are not
needed. It is true that most researchers instinctively feel more
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comfortable with studies embracing large numbers, if only
because the results are less prone to selection bias and they
are more likley to be reproduced in a separate cohort of
patients. This highlights the further point that patient
populations must be carefully scrutinised to exclude both
intrinsic and selection biases. In this respect the Stanton
paper has an apparent advantage over many other studies in
that the patients presented locally to a small number of
hospitals and as a result have been treated in a standardised
manner. In contrast others have included patients who have
been derived from many centres and treated with diverse
therapies. Unless patients presenting in Liverpool have an
unusual form of the disease or the treatment was not stan-
dard, this must be the major point in favour of the Stanton
investigation. That the study is not complicated by adjuvant
therapy also simplifies interpretation of results. However it
should be pointed out that no account was taken of the
nature of, or response to, systemic treatment given at recur-
rence. This could be important as the end-point of analysis
was not disease-free interval but overall survival.
The potential problems of selection bias have to be con-
sidered and are illuminating. A total of 749 patients were
entered into the study but estimates could only be performed
on 329 cases because two of the four recruiting hospitals had
closed and material was not available for analysis. For
various methodological reasons valid results for assessment
of S-phase were available in only 226 patients. This
represents 30% of the total population and 69% of the
tumours analysed. Whilst these figures are low they are no
worse than those in other comparable studies. Nevertheless a
value judgment has to be made on whether these exclusions
are likley to invalidate the conclusions. The findings clearly
illustrate the problems in performing these type of investiga-
tions, i.e. that, even under strictly controlled conditions, S-
phase fraction analysis will eventually be applied to the
minority of patients initially enrolled for study.
In terms of analysis, Stanton et al. simply split their data
into groups on the basis ofmedian values whilst other groups
have been prepared to search through data to find and use
potentially more optimal cut-off values. The latter can be a
dangerous game if done retrospectively and never applied to
a prospective series. Nevertheless it would have been interest-
ing to know whether other levels of discrimination could
have substantially improved the prognostic power of S-phase
analysis in the Liverpool series.
Finally, a common cause for conflicting results is method-
ology. Although the methods used for 'S' phase analysis by
flow cytometry are standard, there are technical difficulties,
particularly in gating out cellular debris and calculating S-
phases by computer programmes. These can lead to different
laboratories allocating differing values for the S-phase of the
same tumour (Joensuu, 1989). There is thus an immediate
need for experts in flow cytometry to formulate some simple
guidelines for interpreting results so that agreement may be
obtained between groups including those who are not so
conversant with the nuances of the technology.
So where does this leave us and does the present paper
further our understanding of 'S' phase analysis as a pro-
gnositic factor for breast cancer? The publication does have
the following attributes, (i) the work meets most of the
McGuire criteria, (ii) the results identify some of the prob-
lems in the routine assessment of S-phase and (iii) the discus-
sion highlights certain deficiencies in already published data.
It is true that the results are largely negative and somewhat
at odds with other publications. However exclusion on the
basis of negativity of results risks biasing the literature in
favour of positive findings and, whilst minority views can
muddle the waters, they can also be the source of unexpected
progress.
It would be wrong to end on a low-key note. Flow
cytometry is a powerful technique and the evolution of novel
molecular and immunological tools means that in the very
near future it should be possible to replace S-phase analysis
with technologies which will more accurately reflect the pro-
liferative capacity of virtually all breast tumours. Many of
these techniques will be applicable to archival material which
will accelerate the correlation with clinical outcome. My plea
is that when these results are published researchers assess
their merits using the McGuire guidelines and that editors
should be prepared to accept equally both confirming and
confounding data.
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